Ozanimod Results Promising in Crohn’s Disease, Ulcerative Colitis, Phase 2 Trial Data Show

Ozanimod Results Promising in Crohn’s Disease, Ulcerative Colitis, Phase 2 Trial Data Show
Celgene recently presented positive data from two Phase 2 studies — the STEPSTONE and TOUCHSTONE studies — for the company’s investigational compound ozanimod (RPC-1063) as a therapy for Crohn’s disease and ulcerative colitis at the World Congress of Gastroenterology at ACG2017  in Orlando, Florida, Oct. 13-18. “The new STEPSTONE findings further validate our hypothesis of ozanimod in Crohn’s disease and the latest data from the TOUCHSTONE study continue to support the potential of ozanimod to provide continued efficacy in ulcerative colitis at 92 weeks,” Terrie Curran, president of Celgene Inflammation and Immunology, said in a press release. “The results in both studies are highly encouraging as we execute pivotal studies of ozanimod in Crohn’s disease and ulcerative colitis in hopes of advancing oral treatment options for these patients.” The ongoing, open-label STEPSTONE study (NCT02531113) enrolled patients with moderately to severely active Crohn’s disease and has two periods — induction and extension. Patients are first enrolled in an induction period of 12 weeks, where they all receive 1.0 mg of ozanimod daily. Patients who complete the induction period may then be eligible to enter the 100-week extension period where they will continue to receive study medication. Celgene presented the data for the induction period that included 69 patients (with a mean age of 37.7 years) with moderately to severely active Crohn’s disease. Following the 12-week tr
Subscribe or to access all post and page content.